8-K

                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15 (d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

       Date of Report (Date of earliest event reported): November 16, 2005

                            POINT THERAPEUTICS, INC.
               (Exact Name of Registrant as Specified in Charter)

                 DELAWARE                                  0-19410
       (State or Other Jurisdiction               (Commission File Number)
             of Incorporation)

                 155 FEDERAL STREET, BOSTON, MASSACHUSETTS 02110
                    (Address of Principal Executive Offices)

       Registrant's telephone number, including area code: (617) 933-2130

                                       N/A
          (Former Name or Former Address, if Changed Since Last Report)



Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17
    CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
    240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
    Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
    Exchange Act (17 CFR 240.13e-4(c))




Item 8.01 Other Events

          Point Therapeutics, Inc. ("Point") issued a press release on November
          16, 2005 announcing that they presented positive results from Point's
          Phase 2 study of talabostat in combination with docetaxel in patients
          with advanced non-small cell lung cancer in a poster session at the
          AACR-EORTC-NCI International Conference on Molecular Targets and
          Cancer Therapeutics in Philadelphia, PA.


          A copy of the press release dated November 16, 2005 is being filed as
          Exhibit 99.1 to this Current Report on Form 8-K.



Item 9.01 Financial Statements and Exhibits.

          (c) Exhibits.

          99.1 - Press release issued by Point dated November 16, 2005.




                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                       POINT THERAPEUTICS, INC.


November 16, 2005                      By:    /s/ Donald R. Kiepert, Jr.
                                              --------------------------
                                       Name:  Donald R. Kiepert, Jr.
                                       Title: President, Chief Executive Officer




                                  EXHIBIT INDEX

The following exhibit is filed herewith:

Exhibit        Description
- -------        -----------

99.1           Press release issued by Point Therapeutics, Inc. ("Point") on
               November 16, 2005 announcing that they presented positive results
               from Point's Phase 2 study of talabostat in combination with
               docetaxel in patients with advanced non-small cell lung cancer in
               a poster session at the AACR-EORTC-NCI International Conference
               on Molecular Targets and Cancer Therapeutics in Philadelphia, PA.

EX-99.1

                                                                    Exhibit 99.1

Point Therapeutics Announces Positive Results at AACR-EORTC-NCI Conference from
Phase 2 Talabostat Non-Small Cell Lung Cancer Study

     BOSTON--(BUSINESS WIRE)--Nov. 16, 2005--Point Therapeutics, Inc.
(NASDAQ:POTP) presented positive results from the company's Phase 2 study of
talabostat in combination with docetaxel in patients with advanced non-small
cell lung cancer (NSCLC) in a poster session at the AACR-EORTC-NCI International
Conference on Molecular Targets and Cancer Therapeutics in Philadelphia, PA.
     The trial enrolled 55 patients--42 of whom met evaluability criteria for
response. Five patients demonstrated a clinical response to treatment as defined
by World Health Organization criteria (a 50% or greater reduction in tumor size)
for a response rate of 11.9%. Two of these patients had a complete response,
defined as a complete disappearance of their tumor. The first complete responder
was observed in March 2005 and the second in April 2005; both patients continue
to be in complete response. The current Kaplan-Meier estimate of median
progression-free survival is 4.2 months and median survival is estimated at 8.4
months. To date, the one-year survival rate is 48% for the 31 patients who have
been in the study for at least one year.
     The objective response rate, progression-free survival, median survival and
one-year survival rates compare favorably to the historical docetaxel data from
three randomized, independent Phase 3 clinical trials. In these historical
trials, approximately 96% of all patients had failed only a first-line treatment
while 4% had failed both first- and second-line treatment. By contrast, in the
talabostat/docetaxel combination trial, 64% of patients had failed first-line
treatment while 36% had failed both first- and second-line treatment.
Additionally, approximately 75% of the patients in the talabostat study had
received a prior platinum-based combination treatment with either docetaxel or
another taxane.
     "It is important to note that of the five responders, two had a complete
response, which is very unusual and quite significant in a second- or third-line
setting in advanced non-small cell lung cancer. We also saw a clinically
meaningful increase in progression-free survival--which is the primary clinical
endpoint for regulatory approval in talabostat's Phase 3 non-small cell lung
cancer trials," said Dr. Casey Cunningham, an oncologist at Mary Crowley Medical
Research Center in Dallas, TX and a member of Point's Clinical Advisory Board.
"Also, the median and one-year survival results compare favorably to
historically reported results, and talabostat did not substantially alter the
safety profile of docetaxel. In addition, the oral availability of talabostat is
convenient for patients and offers physicians dosing flexibility. I believe that
talabostat has the potential to become an important treatment for non-small cell
lung cancer and that the initiation of Point's Phase 3 clinical program in
October was a significant step towards achieving this goal."
     "Point reached a major milestone in the company's history when we initiated
our Phase 3 program in non-small cell lung cancer. We are actively enrolling
patients into the study and our first patient has received study medication,"
said Don Kiepert, President and CEO of Point Therapeutics, Inc. "We are excited
about the potential for talabostat to become an important addition to the
therapies available to the non-small cell lung cancer patient population."

     About Point Therapeutics, Inc.:

     Point is a Boston-based biopharmaceutical company developing a family of
dipeptidyl peptidase (DPP) inhibitors for use in cancer, type 2 diabetes and as
vaccine adjuvants. Point is currently studying its lead product candidate,
talabostat, in a Phase 3 trial in NSCLC. Point is also studying talabostat in
several Phase 2 trials, including as a single agent in metastatic melanoma, in
combination with cisplatin in metastatic melanoma, in combination with rituximab
in advanced chronic lymphocytic leukemia, and in combination with gemcitabine in
metastatic pancreatic cancer. In addition, Point's portfolio includes two other
DPP inhibitors in preclinical development--PT-630 for type 2 diabetes, and
PT-510 as a vaccine adjuvant.

     Certain statements contained herein are not strictly historical and are
"forward looking" statements as defined in the Private Securities Litigation
Reform Act of 1995. This information includes statements with respect to the
company's clinical development programs, the timing of initiation and completion
of its clinical trials, and the potential of talabostat to become an important
treatment for non-small cell lung cancer. Forward-looking statements are
statements that are not historical facts, and can be identified by, among other
things, the use of forward-looking language, such as "believes," "feels,"
"expects," "may," "will," "should," "seeks," "plans," "schedule to,"
"anticipates" or "intends" or the negative of those terms, or other variations
of those terms of comparable language, or by discussions of strategy or
intentions. A number of important factors could cause actual results to differ
materially from those projected or suggested in the forward looking statement,
including the risk factors described in Point's quarterly report on Form 10-Q
for the quarter ended September 30, 2005 and from time to time in Point's
periodic and other reports filed with the Securities and Exchange Commission.


     CONTACT: Point Therapeutics, Inc.
              Sarah Cavanaugh, 617-933-7508